Oravax, Inc.

Natural Environmental Research Council

Oxford University Innovation Ltd

Natural Environment Research Council

Polly Roy

Timothy J French

Thomas P Monath

Farshad Guirakhoo

Jacques Pappo

Thomas H Ermak

Richard D Nichols, Jr

A protective effect against bluetongue infection in susceptible mammals which is obtained by innoculating said mammals with a polypeptide comprising at least an antigenic portion of bluetongue virus structural protein VP2 in antigenic form produced by transforming a host with a recombinant expression vector having a DNA segment coding for said polypeptide.

Use of bluetongue virus proteins as vaccine components

Method of inducing a mucosal and or/systemic immune response in a host, comprising the step of administering to the host an effective amount of a Bluetongue antigen in the form of virus like and/or virus core like particles. Vaccines are also provided.

Oral immunization with multiple particulate antigen delivery system

Antigens are produced by self-assembly of polypeptide components. The production of bluetongue virus antigens (BTV) in the form of assembled particles comprising separate polypeptide components, particularly proteins VP2, VP3, VP5 and VP7 is described.

Production of antigens by self-assembly of polypeptide components

Antigens in particulate form are provided wherein chimeric antigens having foreign epitopes are presented on or within virus-like particles (VLPs) or virus core-like particles (CLPs). The VLPs and CLPs are immunogenic and are useful in producing vaccine formulations.

Growing community of inventors

Oxford, United Kingdom

Polly Roy